79 citations · 131 across the 5 of their papers we have counts for
5 papers
Estimating SARS-CoV-2 Seroprevalence
Samuel P. Rosin, Bonnie E. Shook-Sa, Stephen R. Cole +1
Governments and public health authorities use seroprevalence studies to guide responses to the COVID-19 pandemic. Seroprevalence surveys estimate the proportion of individuals who…
Odds Ratios are far from "portable": A call to use realistic models for effect variation in meta-analysis
Mengli Xiao, Haitao Chu, Stephen Cole +4
Objective: Recently Doi et al. argued that risk ratios should be replaced with odds ratios in clinical research. We disagreed, and empirically documented the lack of portability of…
Generalizing trial evidence to target populations in non-nested designs: Applications to AIDS clinical trials
Fan Li, Ashley L. Buchanan, Stephen R. Cole
Comparative effectiveness evidence from randomized trials may not be directly generalizable to a target population of substantive interest when, as in most cases, trial participant…
Sensitivity analyses for effect modifiers not observed in the target population when generalizing treatment effects from a randomized controlled trial: Assumptions, models, effect scales, data scenarios, and implementation details
Trang Quynh Nguyen, Benjamin Ackerman, Ian Schmid +2
Background: Randomized controlled trials are often used to inform policy and practice for broad populations. The average treatment effect (ATE) for a target population, however, ma…
Sensitivity analysis for an unobserved moderator in RCT-to-target-population generalization of treatment effects
Trang Quynh Nguyen, Cyrus Ebnesajjad, Stephen R. Cole +1
In the presence of treatment effect heterogeneity, the average treatment effect (ATE) in a randomized controlled trial (RCT) may differ from the average effect of the same treatmen…